Literature DB >> 22580211

Conception, preparation and properties of functional carrier particles for pulmonary drug delivery.

Marcin Odziomek1, Tomasz R Sosnowski, Leon Gradoń.   

Abstract

BACKGROUND: The effectiveness of aerosol therapy is significantly reduced by the mucus layer covering the airways of the tracheobronchial tree. According to the present concept, drug particles are delivered to the lung together with the functional carrier particle that facilitates both the drug transport into the lungs and the penetration of deposited particles through the mucus. The approach of manufacturing multi-component powders with mucoactive compounds and anti-asthmatic medicines (DSCG) bound together in a single particle is additionally considered.
METHODS: Powders were produced with the spray-drying technique from aqueous precursor solutions containing pure low molecular weight dextran, pure mannitol and dextran/mannitol-N-acetyl cysteine (NAC) mixtures (4:1 and 1:1). NAC has been selected for this purpose as a compound, which is known to be mucolytic. Dextran and mannitol are potentially applicable in the field of inhalation drug delivery. They have been used as stabilizers of functional carrier particles. Powders were characterized for their yield and physicochemical properties including: morphology (SEM), moisture content and thermal properties (DSC). Aerosol performance was determined with NGI impactor after standardized aerosolization of the produced powders in a commercial DPI.
RESULTS: Particle size distributions of dextran-NAC powders were characterized by high fine particle fraction (45-62%), which assures good particle deposition in the lower airways. The thermodynamic properties of the powders based on the temperature of the glass transition T(g) (50-63 °C) suggest the required stability during storage at moderate humidity.
CONCLUSIONS: Preliminary examination of the required properties of these particles confirms their potential as functional carriers for pulmonary drug delivery.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580211     DOI: 10.1016/j.ijpharm.2012.04.067

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

Review 1.  Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation.

Authors:  Anil Kumar; Fei Chen; Anbu Mozhi; Xu Zhang; Yuanyuan Zhao; Xiangdong Xue; Yanli Hao; Xiaoning Zhang; Paul C Wang; Xing-Jie Liang
Journal:  Nanoscale       Date:  2013-09-21       Impact factor: 7.790

2.  Supercritical CO₂-Assisted Spray Drying of Strawberry-Like Gold-Coated Magnetite Nanocomposites in Chitosan Powders for Inhalation.

Authors:  Marta C Silva; Ana Sofia Silva; Javier Fernandez-Lodeiro; Teresa Casimiro; Carlos Lodeiro; Ana Aguiar-Ricardo
Journal:  Materials (Basel)       Date:  2017-01-18       Impact factor: 3.623

Review 3.  Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.

Authors:  You Xu; Aneesh Thakur; Yibang Zhang; Camilla Foged
Journal:  Pharmaceutics       Date:  2021-01-28       Impact factor: 6.321

Review 4.  Inhaled aerosols: their role in COVID-19 transmission including biophysical interactions in the lungs.

Authors:  Tomasz R Sosnowski
Journal:  Curr Opin Colloid Interface Sci       Date:  2021-03-24       Impact factor: 6.448

5.  Dextran Mass Ratio Controls Particle Drying Dynamics in a Thermally Stable Dry Powder Vaccine for Pulmonary Delivery.

Authors:  Myla Manser; Blair A Morgan; Xueya Feng; Rod G Rhem; Myrna B Dolovich; Zhou Xing; Emily D Cranston; Michael R Thompson
Journal:  Pharm Res       Date:  2022-07-19       Impact factor: 4.580

Review 6.  A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers.

Authors:  Ruhisy Mohd Rasul; M Tamilarasi Muniandy; Zabliza Zakaria; Kifayatullah Shah; Chin Fei Chee; Ali Dabbagh; Noorsaadah Abd Rahman; Tin Wui Wong
Journal:  Carbohydr Polym       Date:  2020-08-18       Impact factor: 9.381

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.